Idera Pharma (IDRA) Reports Q3 Loss of $0.10/Share

Idera Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the third quarter ended September 30, 2015.

Weve made a great deal of progress at Idera through the first three quarters of 2015, which sets up our company for a number of important catalysts in this last quarter of the year, stated Vincent Milano, Ideras Chief Executive Officer. As we announced... More

Idera Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare diseases, today reported its financial and operational results for the third quarter ended September 30, 2015.

Weve made a great deal of progress at Idera through the first three quarters of 2015, which sets up our company for a number of important catalysts in this last quarter of the year, stated Vincent Milano, Ideras Chief Executive Officer. As we announced... More

Idera Pharmaceuticals Presents Preclinical Data Demonstrating Potent Anti-Tumor Response From Combination Treatment With Intra-Tumoral IMO-2125 and Anti-PD-1 Monoclonal Antibody at AACR-NCI-EORTC Inte

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical data demonstrating potent and systemic anti-tumor activity in preclinical cancer models with intra-tumoral administration of IMO-2125 in combination with an anti-PD-1 monoclonal antibody (mAb).  IMO-2125 is a synthetic oligonucleotide-based agonist of Toll-like receptor 9 discovered and developed by Idera.  There are currently two anti-PD-1 antibodies that have been recently approved for the treatment of melanoma and... More

Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting

- Poster Presentation to Reveal First Clinical Data for IMO-8400 as Potential Treatment for Waldenströms Macroglobulinemia -

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that new data from the Phase 1/2 clinical trial for IMO-8400, a TLR 7,8 and 9 antagonist, being evaluated for the treatment of relapsed, refractory patients suffering from Waldenströms Macroglobulinemia, will be presented at the 2015 American Society of Hematology... More